Three Governors release statement re cooperation
Governor Ned Lamont of Connecticut, Governor Gina Raimondo of Rhode Island, and Governor Charlie Baker of Massachusetts have released a joint statement regarding regional policy....
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Governor Ned Lamont of Connecticut, Governor Gina Raimondo of Rhode Island, and Governor Charlie Baker of Massachusetts have released a joint statement regarding regional policy....
SpringWorks reports that the first patient has been dosed in the Phase 2b ReNeu clinical trial evaluating mirdametinib (formerly PD-0325901), an oral, small molecule designed...
Thetis Pharmaceuticals reports it has received a Fast-Track Small Business Innovation Research Grant from the National Institutes of Health (for development of an innovative new therapy,...
Hyperfine Research, housed in Jonathan Rothberg’s Guilford-based 4Catalyzer health technology incubator, has announced that it has developed “the world’s first portable, low-cost magnetic resonance imaging (MRI)...
Elidah has announced the launch of ELITONE®, the first and only patented medical device providing non-invasive treatment for stress urinary incontinence in women. ELITONE is the...
A Farmington biotech working with genetic engineering and microbiome science to develop skin disease treatments said it has raised its largest money to date. Azitra...
CaroGen reports that the United States Patent and Trademark Office has issued CaroGen’s first composition of matter patent for its Artificial Virus (AV) for Infectious Diseases...
Achillion reports that the FDA has granted Breakthrough Therapy designation for danicopan (ACH-4471) for treatment in combination with a C5 monoclonal antibody for patients with...
It’s been more than nine years since state lawmakers approved borrowing more than $1 billion to build-up Connecticut’s bioscience stature. A newly issued report from...
Alexion and Stealth BioTherapeutics Corp have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase 3 study in people...